Antares pharma inc.

XYOSTED is a prescription medicine that contains testosterone. XYOSTED is used to treat adult men who have low or no testosterone due to certain medical conditions. It is not known if XYOSTED is safe and effective for use in children younger than 18 years old. Improper use of XYOSTED may affect bone growth in children.Apr 13, 2022 · Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug delivery. Halozyme on ... Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need for a needle.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...

... Antares Pharma, Inc.'s and/or its affiliates (collectively “Antares”) or Antares co-branded websites. If you do not agree to the terms and conditions of ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Apr 14, 2022 · Credit: Arek Socha from Pixabay. Halozyme Therapeutics has signed a definitive agreement for the acquisition of all of the outstanding shares of Antares Pharma in a deal valued at nearly $960m or $5.60 for each share, in cash. A speciality pharmaceutical firm, Antares focuses on developing pharmaceutical products and technologies to address ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …Exchange NASDAQ More. Industry Medical Instruments & Supplies More. Sector Healthcare More. 51-200 Employees. Based in Ewing, New Jersey. Antares Pharma is …ANTARES PHARMA INC. · Home · Marca · ANTARES PHARMA INC. Non ci sono articoli da mostrare. Categorie.Antares Pharma Inc. Ticker ATRS. Exchange NASDAQ More. Industry Medical Instruments & Supplies More. Sector Healthcare More. 51-200 Employees. Based in Ewing, New Jersey. Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems.

Address Medical Inquiries to: Antares Pharma, Inc. Medical Communications 100 Princeton South, Suite 300 Ewing, NJ 08628, 1-855-Otrexup (1-855-687-3987) Nonclinical Toxicology. No Information provided. Use In Specific Populations Pregnancy Risk Summary. Based on published reports and methotrexate’s …

Antares Pharma, Inc. (Amex:AIS) today announced an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to provide its needle-free injection system exclusively for use with a currently unnamed product in the U.S. Under the terms of the agreement, Teva will purchase all of its requirements for the injection system from …

ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 1-32302: 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South, Suite 300, Ewing, ...EBITDA of $420 million to $440 million, representing growth of >30% over 2022. EBITDA excludes the impact of amortization costs related to the Antares Pharma acquisition.1 Non-GAAP diluted earnings per share of $2.65 to $2.75, representing growth of 20% over 20221.Mar 29, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ... Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information. Antares Pharma, Inc. (NASDAQ: ATRS)’s sale to Halozyme Therapeutics, Inc. for $5.60 per share in cash. If you are an Antares Pharma shareholder, ...Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...Antares Pharma Inc. Follow. 3 results. BusinesscategoryHalozyme bolsters drug delivery business with $960 mln Antares deal April 13, 2022. MarketscategoryKroger ...

18. 10. 2021 ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered ...Apr 13, 2022 ... offered to acquire specialised biopharmaceutical business Antares Pharma Inc. for roughly 1 billion dollars. Halozyme released a Statement ...Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) today announced the appointment of Paul K. Wotton, Ph.D., as the Company’s President and Chief Executive Officer effective immediately. Dr. Wotton previously served as President and Chief Operating Officer. Concurrently, Jack E. Stover has resigned as both …

Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. We develop, manufacture and commercialize, for …

Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million.Reinventing the patient experience. The patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes. 2015-2023. Halozyme, Inc.ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) ...0. (Reuters) -Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc, the companies said on Wednesday. San Diego-based Halozyme offers delivery technology that enables high volumes of a drug to be injected under the skin, potentially …Device Type: Auto-Injector: Dosage Type: Fixed for viscous and aqueous formulations: Injection Volume: 0.2-1.0ml Injection Type: SC or IM: Primary Container:Mattel Inc.’s slogan is “The World’s Mattel.” The corporation clearly expresses that its mission is to make a difference in a global scale through effectively serving children in need.On April 12, 2022, Antares Pharma, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Halozyme Therapeutics, Inc., a Delaware corporation (“ Halozyme ”), and Atlas Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Halozyme ...

Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. The Company …

EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Home :: Antares Pharma. As of May 24, 2022 Halozyme completed its acquisition of Antares Pharma, Inc., creating a leading drug delivery business with broadly licensable opportunities across the ENHANZE® and Antares’ auto injector technologies. View details here and send questions to [email protected]. Continue to Site.Legal Name Antares Pharma, Inc. Stock Symbol STU:MJC. Company Type For Profit. Contact Email [email protected]. Phone Number 7634761009. Antares Pharma is a revenue-generating product-focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved …Exhibit 99.1 . Halozyme Completes Antares Pharma Acquisition . SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”).. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at …Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, manufacturing, and …Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ...27 Oct, 2021, 11:30 ET. NEW YORK, Oct. 27, 2021 /PRNewswire/ -- The testosterone replacement therapy market size is expected to increase by USD 113.54 million from 2019 to 2024, registering a CAGR ...Reinventing the patient experience. The patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes. 2015-2023. Halozyme, Inc. Antares Pharma, Inc. (Antares or 'the company') is a drug device company that develops and markets self-injection pharmaceutical products and technologies. The company develops these products with its partners and is designed to provide functional and commercial advantages, such as reduced side effects, improved safety and efficacy and …May 19, 2022 ... Acquisition | ANTARES PHARMA INC | 25th May 2022 · ANTARES PHARMA INC will be removed from the Index. · The weight of ANTARES PHARMA INC (ATRS.Description. Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral …Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …

Antares Pharma, Inc. (Amex:AIS) today announced an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to provide its needle-free injection system exclusively for use with a currently unnamed product in the U.S. Under the terms of the agreement, Teva will purchase all of its requirements for the injection system from …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified ...Instagram:https://instagram. sprint t mobilecompanies that pay the highest dividendsgld stock dividendinvestment consulting services Source: Antares Pharma, Inc. March 29, 2022 07:00 ET A ntares P harma A nnounces FD A A pproval Of TLA N D O™, an Oral Treatment for Testosterone R epl acement Therapy C om m er c ial launc h ex pec ted in 2Q 2022 E W IN G , N .J ., M ar c h 29, 2022 ( G LO B E N E W S W IR E ) - - A ntar es P har m a, Inc . ( N A S D A Q : A T R S ) ( the “ C om … mpgfxadmp Antares Pharma Inc. announced that Ferring Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON (somatropin [rDNA origin]) for injection, and the needle-free delivery system to be … fridays stock market Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners,